Moderna, Inc.
MRNA Healthcare · Biotechnology · US
Moderna is a biotechnology company based in Cambridge, led by chief executive Stéphane Bancel. It develops medicines using messenger RNA, or mRNA: instructions that direct the body’s cells to make proteins.
| Reported | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|
| Revenue | $19.3B | $6.8B | $3.2B | $1.9B | $2.5B | |
| EPS | $20.12 | −$12.33 | −$9.28 | −$7.26 | −$7.10 | |
| Free cash flow | $4.6B | −$3.8B | −$4.1B | −$2.1B | −$2.0B | |
| Net debt | −$9.0B | −$8.0B | −$7.0B | −$5.2B | −$1.6B |
What happened
- Guidance Moderna outlined about $4 billion in 2027 cash costs, projected annual spending of $4 billion–$4.5 billion through 2030 and reiterated 2026 revenue-growth guidance of 15%–25%.
- Product Moderna and Merck reported that intismeran plus Keytruda reduced melanoma recurrence or death risk by 42% versus Keytruda alone in a Phase 3 trial.
- Results Moderna reported third-quarter revenue of $1.31 billion and net income of $162 million, then raised its 2026 revenue-growth outlook to 15%–25%.
This screen